THOUSAND OAKS, Calif., Feb. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the opening of its manufacturing site in Central Ohio, the newest in its global operations network and the most advanced facility to date.

加利福尼亚州千橡，2024年2月26日/新闻专线/--安进（纳斯达克：AMGN）今天宣布其在俄亥俄州中部的制造工厂开业，这是其全球运营网络中最新的，也是迄今为止最先进的工厂。

'Our new facility, known as Amgen Ohio, was designed with the latest innovation and technology to deliver safe, reliable medicines for 'every patient, every time,'' said Robert A. Bradway, chairman and chief executive officer at Amgen. 'As part of Amgen's global biomanufacturing network, Amgen Ohio will play an important role in helping us address serious disease around the world with our innovative biomedicines.'.

安进董事长兼首席执行官罗伯特·布莱德韦（RobertA.Bradway）说，我们的新工厂被称为俄亥俄州安进（Amgen Ohio），其设计采用了最新的创新和技术，为“每一位患者，每一次”提供安全可靠的药物作为安进全球生物制造网络的一部分，俄亥俄州安进公司将通过我们的创新生物医学在帮助我们解决全球严重疾病方面发挥重要作用。”。

The nearly 300,000-square-foot facility will employ 400 full-time staff. It also features open workspaces to foster collaboration and has been designed to meet the highest environmental sustainability standards, in support of Amgen's commitment to achieve carbon neutrality for all operations by 2027.  .

这座占地近30万平方英尺的工厂将雇用400名全职员工。它还拥有开放的工作空间，以促进合作，并旨在满足最高的环境可持续性标准，以支持安进公司到2027年实现所有运营的碳中性的承诺。

'This new Ohio facility is a success story in advanced healthcare manufacturing and the Made-in-America supply chain we need to live and thrive,' said Lt. Governor Jon Husted. 'Winning this project for Ohio creates 400 high-paying jobs and a $40 million annual payroll, supporting families and further growing the Ohio economy.'.

副州长乔恩·赫斯特（JonHusted）说，俄亥俄州的这家新工厂是先进医疗保健制造业和我们生存和发展所需的美国制造供应链的成功案例为俄亥俄州赢得这个项目将创造400个高薪工作岗位和4000万美元的年工资，支持家庭并进一步发展俄亥俄州的经济。”。

Amgen is a strong supporter of the communities in which its staff members work and live. In partnership with Columbus State Community College, Amgen is hosting an inaugural 18-month manufacturing apprenticeship at the site. This program, designed for those new to the field or changing careers, offers a blend of classroom and practical training, aiming to expand opportunities for skilled individuals without the requirement for a formal bachelor's degree..

安进是其员工工作和生活的社区的有力支持者。安进与哥伦布州立社区学院合作，将在该基地举办为期18个月的首届制造学徒培训。该课程专为新手或转行者设计，提供课堂和实践培训相结合的课程，旨在为不需要正式学士学位的技能型人才提供更多机会。。

About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. .

关于安进安进安进致力于通过发现、开发、制造和提供创新的人类疗法，为患有严重疾病的患者释放生物学的潜力。这种方法首先使用先进的人类遗传学等工具来揭示疾病的复杂性，并了解人类生物学的基本原理。。

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. .

安进专注于医疗需求未得到满足的领域，并利用其专业知识，努力寻求改善健康状况和大幅改善人们生活的解决方案。安进自1980年以来一直是生物技术的先驱，现已发展成为世界领先的独立生物技术公司之一，已惠及全球数百万患者，并正在开发具有突破潜力的药物管道。。

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of 'America's Greatest Workplaces' by Newsweek, one of 'America's Climate Leaders' by USA Today and one of the 'World's Best Companies' by TIME.

安进是道琼斯工业平均指数的30家公司之一，也是纳斯达克100指数的一部分。2023年，安进被《新闻周刊》评为“美国最伟大的工作场所”，被《今日美国》评为“美国气候领导者”，被《时代》评为“世界最佳公司”。

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, TikTok, YouTube and Threads.

有关更多信息，请访问Amgen.com，并在X（以前称为Twitter）、LinkedIn、Instagram、TikTok、YouTube和Threads上关注我们。

Amgen Forward-Looking StatementsThis news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd.

安进前瞻性声明本新闻稿包含基于安进当前期望和信念的前瞻性声明。除历史事实陈述外，所有陈述均为可被视为前瞻性陈述的陈述，包括与任何其他公司（包括BeiGene，Ltd.）合作或潜在合作的结果、利益和协同作用的任何陈述。

or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results.

或Kyowa Kirin Co.，Ltd.），Otezla®（apremilast）的业绩（包括预期的Otezla销售额增长和非GAAP每股收益增长的时间），我们对Teneobio，Inc.，ChemoCentryx，Inc.的收购。，或Horizon Therapeutics plc（包括Horizon业务的预期业绩和前景、业绩和机会、此类收购产生的任何潜在战略利益、协同效应或机会，以及Horizon收购对我们未来收购相关费用的任何预期影响），以及收入、营业利润率的估计，资本支出、现金、其他财务指标、预期的法律、仲裁、政治、监管或临床结果或实践、客户和处方模式或实践、报销活动和结果、大流行或其他广泛健康问题对我们业务的影响、结果、进展以及其他此类估计和结果。

Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K.

前瞻性陈述涉及重大风险和不确定性，包括下文讨论的风险和不确定性，以及安进提交的证券交易委员会报告中更详细描述的风险和不确定性，包括我们最近的10-K表年度报告、10-Q表后续任何定期报告以及8-K表当前报告。

Unless otherwise noted, Amgen is providing this information as of the date o.

除非另有说明，安进自o日起提供此信息。

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions.

无法保证前瞻性陈述，实际结果可能与我们预测的结果存在重大差异。我们的业绩可能会受到以下因素的影响：我们在国内外成功营销新产品和现有产品的能力，涉及当前和未来产品的临床和监管发展，最近推出的产品的销售增长，包括生物仿制药在内的其他产品的竞争，制造我们产品的困难或延误以及全球经济状况。

In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment.

此外，我们产品的销售受到第三方付款人（包括政府、私人保险计划和管理式护理提供者）施加的定价压力、政治和公共审查以及报销政策的影响，并可能受到监管、临床和指南发展以及国内外管理式护理和医疗保健成本控制趋势的影响。

Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

此外，我们的研究、测试、定价、营销和其他业务都受到国内外政府监管机构的广泛监管。我们或其他人可以在我们的产品（包括我们的设备）上市后发现其安全性、副作用或制造问题。

Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S.

我们的业务可能会受到政府调查、诉讼和产品责任索赔的影响。此外，我们的业务可能会受到新税法的通过或额外纳税义务的影响。如果我们未能履行我们与美国之间的《企业诚信协议》中的合规义务。

government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our co.

政府，我们可能会受到重大制裁。此外，虽然我们经常为我们的产品和技术获得专利，但我们的专利和专利申请所提供的保护可能会受到我们公司的质疑、无效或规避。

CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media)Jessica Akopyan, 805-440-5721 (media) Justin Claeys, 805-313-9775 (investors)

联系人：安进（Amgen）、千橡（Thound Oaks）、埃莉莎（Elissa Snook）、609-251-1407（media）、杰西卡（Jessica Akopyan）、805-440-5721（media）、贾斯汀·克莱斯（Justin Claeys）、805-313-9775（investors）

SOURCE Amgen

来源：安进